Renal denervation lowers all-cause and cardiovascular mortality in patients with uncontrolled arterial hypertension: a randomised, sham-controlled study.

31 August 2024 (17:30 - 17:42)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Marshall Heradien

Kuils River (South Africa)

4 More presentations in this session

Presentation thumbnail

Effects of Intensive vs Standard Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors: Results from the SPRINT Randomized Trial

Doctor Y. Xiao (Changsha, CN)

Presentation thumbnail

A machine learning algorithm for personalizing intensive blood pressure treatment: derivation from SPRINT/ACCORD-BP trials and validation in CRHCP, a pragmatic implementation trial

Professor Y. Sun (Shenyang, CN)

Presentation thumbnail

Long-term outcomes of intensive blood-pressure control in older patients with hypertension: final six-year results of the STEP trial

Doctor Q. Song (Beijing, CN)

Presentation thumbnail

Fractional flow reserve to determine the appropriateness of percutaneous renal artery intervention in atherosclerotic renovascular hypertension patients: a randomized trial

Professor J. Li (Beijing, CN)

Access the full session

Session thumbnail

Smaller trials, trial updates, and other studies on hypertension

The Event

Event poster

ESC Congress 2024

31 August 2024 17:30 CET

You may be interested in

Congress Session

Smaller trials, trial updates, and other studies on hypertension

Congress Presentation

Renal denervation is one of the pillars of management of resistant hypertension: pro

Congress Presentation

Renal denervation: new evidence and new directions

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources